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Abstract:
Maintenance of adequate tissue perfusion through a dense network of cerebral microvessels is
critical for the perseveration of normal brain function. Regulation of the cerebral blood flow has to
ensure adequate delivery of nutrients and oxygen with moment‑to‑moment adjustments to avoid
both hypo‑ and hyper‑perfusion of the brain tissue. Even mild impairments of cerebral blood flow
regulation can have significant implications on brain function. Evidence suggests that chronic stress
and depression elicits multifaceted functional impairments to the cerebral microcirculation, which
plays a critical role in brain health and the pathogenesis of stress‑related cognitive impairment and
cerebrovascular events. Identifying the functional and structural changes to the brain that are induced
by stress is crucial for achieving a realistic understanding of how related illnesses, which are highly
disabling and with a large economic cost, can be managed or reversed. This overview discusses
the stress‑induced alterations in neurovascular coupling with specific attention to cerebrovascular
regulation (endothelial dependent and independent vasomotor function, microvessel density). The
pathophysiological consequences of cerebral microvascular dysfunction with stress and depression
are explored.
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Introduction

T

he meaning of “stress” is ambiguous
and often refers to life events that
are seen as predominantly negative.
Stress has been defined as a subjective
perception of an adverse environmental
change, which usually leads to a stress
response allowing for adaptation to the new
condition.[1] Different stress stimuli (i.e.,
physical or psychological in nature)
innervate separate regions of the central
nervous system to elicit an appropriate
response.[2] Activation of the autonomic
nervous system and hypothalamic–
pituitary–adrenal (HPA) axis are prominent
features of a stress response, which in turn
impacts immune and metabolic mediators.
These physiological responses operate
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non‑linearly and promote adaptation
through “allostasis,” i.e., reestablishing
homeostasis. [3] In the short term, these
changes may be adaptive; but chronic stress
exposure (i.e., allostasis overload) leads to
maladaptive responses in various body
organs and activates pathophysiological
mechanisms. Indeed, chronic stress acts
as a pre‑disposing and participating factor
in the onset of depression in humans.[4]
Over 350 million people worldwide suffer
from depressive disorders, establishing
depression as a leading cause of disease
burden.[5,6] Importantly, both stress and
depression are linked to cardio [7,8] and
cerebrovascular diseases.[9]
The brain is the key organ of stress reactivity,
coping, and recovery processes. Within
the brain, a distributed neural circuitry
determines what is threatening and thus
stressful to the individual. As such, there
is tight coupling between neural activity
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and cerebral blood flow to meet metabolic demands.
The brain receives energy substrates from its blood
supply, however, the brain lacks a reservoir to store
fuel, thus the brain must dynamically regulate blood
flow to quickly meet the metabolic needs. Failure to
do so has disastrous consequences, and if blood flow
is not well matched to energy demands, then more
subtle brain alterations ensue, leading to chronic
brain injury. The moment‑to‑moment matching of
blood flow to metabolic demand is ensured by the
signaling mechanisms of neurovascular coupling. The
neurovascular unit consists of the cerebral microvessels,
glial cells (astroglia, microglia, and oligodendroglia), and
neurons. Harmonious interactions between neuronal
and endothelial cells must be maintained to ensure
normal cerebral circulation. For example, when neurons
become active, they signal to local arterioles through
astrocytes which generate a calcium wave in response
to neuronal activity to evoke dilation through the release
of potassium ions and other vasodilators to the arteriolar
smooth muscle cells.[10‑12] This response increases local
blood flow and provides the nutrients necessary to
support neuronal function. It has been suggested that
stress impairs this balance.
To date, the effects of stress on neurovascular coupling
has mainly focused on its effects on neurotransmitters,
hormones, and neuronal plasticity. In postmortem
biopsies of patients with a history of depressive
symptoms, the morphology of neurons was altered
leading to a loss in number and synaptic connectivity
causing impairment in synaptic function. [13] More
recent work has established that astrocytes are also an
important target of stress, with both acute and chronic
stressors altering the morphology and the expression
of several astrocyte‑specific proteins. We direct the
readers to excellent reviews describing the impact of
stress on neurons and astrocytes.[14‑16] However, there is
limited information as to what effect stress has on the
cerebrovasculature. The following review will focus on
how stress affects the cerebral vessels. We will describe
briefly the hormonal changes due to stress, the effects on
the cerebrovasculature that seem to be sex‑dependent,
and how pre‑existing cardiovascular disease further
impacts the stress‑induced cerebrovascular dysfunction.
We will also describe the relationship between
cerebrovasculature dysfunction and the upregulation of
oxidative stress and proinflammatory cytokines.

Hormonal Changes during Stress
Acute exposure to stress results in the release of
catecholamines through the sympathetic-adrenomedullary
system and an increase in the stress hormones through
the HPA axis [Figure 1].[17] Stressful stimuli can produce
plasma levels of epinephrine to 10,000 pg/ml.[18] The
44

Figure 1: Acute and chronic hormonal response to stress. Normal
physiological response to stressful stimuli leads to activation of the
hypothalamic–pituitary–adrenal axis. This activation is characterized by
hypothalamic release of corticotropin‑releasing factor which elicits pituitary
release of adrenocorticotropic hormone followed by the adrenocorticotropic
hormone dependent release of cortisol and catecholamines. The production of
corticotropin‑releasing factor and adrenocorticotropic hormone is typically inhibited
by negative feedback from increasing levels of catecholamines and cortisol. When
exposed to chronic stressful stimulus, the normal physiological response is altered.
The negative feedback mechanism is removed and the physiological system
becomes oversensitive to stress. This leads to an increase in circulating stress
hormones that compound rather than returning to homeostatic levels

release of epinephrine and norepinephrine into the
bloodstream increases heart rate, blood pressure, and
respiratory rate, and reflects the typical “fight‑or‑flight
response.” In order to do this, epinephrine triggers the
releases of glucose from temporary storage sites within
the body such as adipose tissue. When faced with physical
stressors, the pituitary gland also releases growth
hormones to enhance metabolic activity. However,
changes in growth hormone responses are seldom seen
when faced with psychological stress.
The activation of the HPA axis results in the secretion of
corticotropin‑releasing hormone, which acts to regulate
the anterior pituitary adrenocorticotropic hormone
to stimulate the adrenal cortex to secrete cortisol
(in humans) and corticosterone (in humans, rats, and
mice). Plasma levels of these hormones can increase
two‑ to five‑fold during stress in humans.[19] Cortisol
reaches every organ by way of the circulation and
facilitates a cascade of physiological changes, including
Brain Circulation ‑ Volume 4, Issue 2, April‑June 2018
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increased metabolism, blood flow, and gluconeogenesis
to facilitate the fight‑or‑flight response. Thus, circulating
cortisol permits coordination between the brain
and body functions that are geared toward coping,
recovering, and adapting to the stressful stimulus.
Cortisol also plays a key role in regulating the stress
response by providing inhibitory feedback at the HPA
axis, thereby terminating the stress response once the
stressor has subsided. Chronic stress, on the other hand,
has been seen to decrease neurogenesis and increase
oligodendrogenesis from neuronal stem cells in regions
of the hippocampus.[20] This means there is an increase in
the white matter in this brain area and an altered cellular
composition, preventing the hippocampus from properly
executing its role within the brain.

Stress and the Cerebral Vasculature
Regulation of cerebral blood flow in a normal
brain is determined by a variety of intrinsic control
mechanisms (myogenic, chemical, metabolic, and
neurogenic) that match cerebral blood flow to
metabolic demand. Overall, the diameter of the cerebral
vessels (vascular tone) is maintained by the sympathetic
nervous system. This sympathetic innervation ensures
that fluctuations in blood pressure do not result in
an overstretching of the cerebral arterioles, or lead to
blood–brain barrier leakage. During acute psychological
stresses, the norepinephrine released improves the ability
to couple blood volume to oxygen demand and thus can
stimulate an increase in cerebral blood flow to increase
perfusion in areas of heightened neuronal activity.[21]
Corroborating evidence for this stress mechanism came
in the form of perfusion functional MRI revealing an
increase in cerebral blood flow in the ventral right
prefrontal cortex and left insula/putamen area during
acute psychological stress.[22] Further, in individuals with
a high‑stress level response, the physiological response to
a mild‑to‑moderate stressor is sustained even when the
stress/task is completed.[22] Indeed, it can take minutes for
heart rate and hours for cortisol to return to their baseline
levels, despite a return to normal behavioral.[17,23] It is
also interesting to note that some studies have suggested
that psychophysiological stressors might compromise
the blood–brain barrier.[24,25] However, a recent study
has shown that acute psychophysiological stress does
not increase blood–brain barrier permeability.[26] Thus,
the acute cerebral vascular responses to stress are likely
emergent to protect the brain and improve cerebral
blood flow to metabolic demand. Whereas, a chronically
stressed brain may be incrementally and deleteriously
remodeled through the repeated neural activation
pattern and sustained hyperactivity of the HPA axis.[27]
Chronic activation of the HPA axis and ANS can have
significant detrimental effects that impact the integrated
Brain Circulation ‑ Volume 4, Issue 2, April‑June 2018

responses of the immune, metabolic, and cardiovascular
systems. The breakdown of this integrated stress response
is referred to as allostatic overload. The neurovascular
endothelium plays a key role in regulating the influx of
essential nutrients, the efflux of toxic substances, ionic
homeostasis of the brain interstitial fluid, and prevent the
brain influx of peripheral substances, neurotransmitters,
etc.[28] Neurovascular endothelial dysfunction contributes
to blood–brain barrier hyperpermeability. Thus, it is
important to ask to what extent chronic stress leads
to endothelial dysfunction in the cerebral circulation.
Figure 2 provides a summary of the main downstream
effects of chronic stress exposure on cerebrovascular
dysfunction.
Overstimulation of the ANS and HPA axis is associated
with an overactivation of the renin–angiotensin system,
which leads to increased levels of homocysteine and
elevated cardiovascular activity accompanied by various
degrees of endothelial damage. Further, glucocorticoids
regulate vascular reactivity by acting on both endothelial
and vascular smooth muscle cells. Increased cortisol
levels decrease nitric oxide (NO; a powerful vasodilator)
bioavailability directly by inhibiting endothelial NO
synthase directly,[29] and indirectly through increasing
the production of oxidative stress through cortisol.[30] An
increase in cortisol has also been shown to decrease cyclic
adenosine monophosphate expression, an important
second messenger mediating vascular function. [31]
Cortisol‑induced dysregulations of NO production in
the endothelium may, therefore, induce some of the
deleterious effects associated with stress. Acute stress
raises the circulatory levels of inflammatory cytokines
interleukin tumor necrosis factor (IL‑6 and TNF‑α)[32] and

Figure 2: Systematic representation of the potential downstream effects
of chronic stress exposure on the cerebrovasculature system. HPA:
Hypothalamic–pituitary–adrenal axis, ANS: Autonomic nervous system,
CD14+: Cluster of differentiation 14, ET‑1: Endothelin 1, TNF‑α: Tumor necrosis
factor alpha, PGI2: Prostaglandin I2, IL‑1 β: Interleukin 1 beta, IL‑6: Interleukin six.
ROS: Reactive oxygen species, BH4, THB: Tetrahydrobiopterin, O2−: Superoxide,
AC: Adenylyl cyclase, cAMP: Cyclic adenosine monophosphate, NF‑kb: Nuclear
factor kappa‑light‑chain‑enhancer of activated B cells, eNOS: Endothelial nitric
oxide synthase, RAAS: Renin–angiotensin–aldosterone system, BP: Blood
pressure, E: Epinephrine, NE: Norepinephrine
45
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results in platelet activation.[33] Thus, it is not surprising to
note that from a peripheral vascular perspective, chronic
psychological stress can contribute to intimal‑medial
thickening,[34] the development of arterial stiffness[35] and
atherosclerosis.[36,37]
There are few studies that have attempted to understand
the effects of stress on the vascular system in the brain.
Previous studies, including our own, have used the
unpredictable chronic mild stress (UCMS) model to
induce depression‑like behaviors in rodents.[38] The
UCMS model exposes rodents to mild daily stresses
that are randomized. The UCMS protocol is considered
to be the most appropriate rodent model for human
clinical depression, based on its ability to reproduce
the development of many human clinical depressive
symptoms, including anhedonia and learned
helplessness.[39] Recently, our laboratory, using the
UCMS model, has established significant pathological
adaptations in the large proximal arteries, which
represent up to 40% of the total cerebrovascular
resistance and their functional response are critical for
preventing pressure fluctuations from reaching the distal
regions of the cerebral circulation.[40,41] Specifically, we
identified that 8 weeks of chronic stress in lean male rats
reduced middle cerebral artery (MCA) vasodilation to
acetylcholine (a potent endothelial‑dependent dilator)
and an exaggerated MCA constriction response to
serotonin (a potent cerebrovascular constrictor).[42] These
adaptations to chronic stress were coupled with increased
levels of oxidative stress and reduced NO bioavailability
in the cerebral vessels. Indeed, pro‑oxidative conditions,
such as UCMS, can alter the balance between constricting
and dilating metabolites, by shifting arachidonic acid
metabolism through cyclooxygenase to the production
of vasoconstricting metabolites (e.g., thromboxane) that
can compete against the vasodilatory stimulus from NO,
prostacyclin, or other vasodilators.[43] Others have shown
that chronic stress, induced by immobilization, decreased
the cerebral vascular hemodynamic response to electrical
stimulation, a reduction and delay in the blood volume
recruitment through the pila arterioles, implying overall
alterations to the cerebrovascular system, including
arteries and capillaries.[44] Further, the impaired vascular
responses were accompanied by a downregulation
in neuron NO synthase and heme oxygenase‑2 and
enhanced inducible NO synthase (iNOS) expression.
The increased iNOS expression may indicate changes
in inflammation‑mediated signaling pathways and
increased neurotoxicity.[44] In addition to the endothelial
damage, 7 days of stress (induced by a variety of
stress stimuli: foot shocks, forced swim, restraint, and
oscillation) greatly reduced vasodilation of parenchymal
arterioles to neuronal stimulation and impaired dilation
of isolated parenchymal arterioles to external potassium
ions.[45] These data would suggest a defect in smooth
46

muscle inwardly rectifying potassium ions channel
function with stress. It was postulated that the chronic
stress resulted in a glucocorticoid‑mediated decrease
in functional potassium channels in the parenchymal
arterioles myocytes, which rendered the arterioles less
responsive to potassium ions released from astrocytic
endfeet during neurovascular coupling, leading to
impairment of this process.[45]
The total length of capillaries in the human brain
is approximately 600 km and almost all neuron is
supplied blood and nutrients by its own capillary.
Neovascularization is an innate physiologic
response by which tissues respond to various stimuli
through arteriogenesis (collateral remodeling) and
angiogenesis (new vessel formation from existing
vessels). Our laboratory has recently demonstrated a
significant reduction in cerebral microvessel density in
male lean rats after 8 weeks of UCMS.[42] In contrast, using
the social defeat model of chronic stress, Pearson‑Leary
et al.[46] indicated that microvessel density in the brain was
increased. It was postulated that increase in microvessel
density would provide metabolic support following
increased neural activity. These differing results may
be a consequence of different stress models (social
stress vs. UCMS), or more likely the duration of stress
imposed (7 days vs. 8 weeks), and the different animal
model utilized (Lean Zucker rat vs. Sprague Dawley
rat). Irrespective, the mechanism by which chronic stress
results in decreased angiogenesis in the brain is not fully
understood. A previous study has shown that the balance
between oxidant stress and endothelial function (e.g., NO
bioavailability and altered arachidonic acid metabolism)
were key factors involved in the progression and severity
of microvascular rarefaction.[47] Both arteriogenesis and
angiogenesis are tightly modulated by environmental
cues and in likely differ under physiologic and disease
conditions. Further, these processes are critically
dependent on expression of vascular endothelial
growth factors (VEGF).[48‑50] While VEGF is an essential
trigger to initiate angiogenesis, evidence suggests that
thrombospondin‑1 (TSP‑1) is an important factor for
capillary regression and/or pathologically mediated
rarefaction.[51] Indeed, a fine bidirectional interaction
exists between TSP‑1, VEGF, and NO. For example,
TSP‑1 can negatively regulate NO signaling,[52,53] and
in turn, decreased NO production can induce TSP‑1
expression. [54] TSP‑1 can also interfere with VEGF
binding to its receptor.[55,56] When TSP‑1 is elevated, the
VEGF signal pathways can be endogenously inhibited,
regardless of whether VEGF levels are elevated.
Further, NO simultaneously induces vasodilatation and
enhances VEGF expression.[57] Evidence suggests that
the processes of oxidative stress and inflammation on
microvascular rarefaction are interconnected. Reactive
oxygen species stimulate the induction of VEGF
Brain Circulation ‑ Volume 4, Issue 2, April‑June 2018
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expression in endothelial cells, smooth muscle cells, and
macrophages.[58,59] In addition, up‑regulation of TSP‑1 is
mediated by superoxides.[60] Our laboratory has made a
similar observation in obese Zucker rats (OZR; a model
for metabolic syndrome, MetS), where TSP‑1 expression
can be elevated up to 2‑fold in OZR whole brain extracts,
with either VEGF protein expression being unchanged
or slightly elevated in OZR compared to similar‑aged
healthy lean controls (PD Chantler and IM Olfert
unpublished data).

Sex‑specific differences

Sex differences have been established in the stress‑related
hormonal secretion, whereby females, regardless
of age, have an increased hormonal secretion in
comparison to males.[61] In premenopausal women with
an ovariectomy, a significant reduction of ACTH and
cortisol are found.[62] Further, there are sex differences
in the cognitive consequences of repeated stress, with
males showing impairment of hippocampal‑dependent
memory, whereas females do not. [63‑65] In men and
women, neural activation patterns to the same tasks are
quite different between the sexes even when performance
is similar.[66] This leads to the concept that men and
women often use different strategies to approach and
deal with issues in their daily lives, in part because of
the subtle differences in brain architecture.
Recent data demonstrated important sex‑specific
differences in the response to chronic stress. Using a
mild UCMS protocol, female Wistar rats were found to
have a reduced serotonergic activity in the hippocampus
and reduced dopaminergic activity in the prefrontal
cortex. This disparity was not identified in male
rats.[67] Sex‑differences have also been reported in the
dysregulation of the HPA axis, whereby higher serum
corticosterone concentrations were reported in female
versus male rats.[68,69] These data would suggest that
females may be more vulnerable to the UCMS model
than the male sex. Indeed, we have previously shown
that female rats display a more phenotypically severe
depressive state compared to male rats.[70] At the neural
level, exposure to chronic stress results in dendritic
atrophy of neurons in the prefrontal cortex in male rats
but dendritic hypertrophy in female rats.[71] However,
dendritic hypertrophy was absence in ovariectomized
female rats, suggesting that ovarian hormones modulate
the morphological changes with stress.
These data, both in human and preclinical models,
would suggest that chronic stress may affect the
cerebrovasculature differently in men and women or to
a different magnitude of response. However, despite a
more phenotypically severe depressive state in female
compared to male rats, female rats demonstrate a better
MCA endothelial‑dependent dilation (albeit lower to
Brain Circulation ‑ Volume 4, Issue 2, April‑June 2018

female nonstressed rats) compared to male rats exposed
to UCMS.[70] The vascular protection from UCMS in
females appeared to reflect a superior maintenance of
endothelial function, with more normal levels of NO,
hydrogen peroxide (another endothelium‑dependent
vasodilator), prostacyclin, and thromboxane. However,
the protective effect in female rats was dependent
on the maintenance of a normal sex hormone profile,
as ovariectomized females before UCMS abolished
the protective effect and resulted in cerebrovascular
outcomes being virtually identical to those in males.
Previous studies have shown not only the protective
effects of estrogen on vascular endothelial function
through its action on promoting the bioavailability
of NO, prostacyclin, and potentially other dilator
metabolites,[72,73] but also the ability of estrogen to blunt
a pro‑oxidant or pro‑inflammatory environment.[74,75]

The role of preexisting cardiovascular disease

The presence of preexisting cardiovascular and metabolic
diseases (obesity, MetS, and diabetes) has been shown
to dysregulate the HPA axis with neuroendocrine
hyperresponsiveness to different neuropeptides and
acute stress challenges.[76‑78] With diabetes, in addition
to an increased plasma adrenocorticotrophic hormone,
RNA expression of corticosterone, and hypothalamic
corticotrophin‑releasing hormone are upregulated.[79]
We have also established that circulating corticosterone
was elevated in MetS compared to lean control rats, and
that circulating corticosterone concentrations was further
elevated with exposure to chronic stress.[42,80] Such data
point toward vascular dysfunction. Indeed, there is strong
evidence linking existing vascular dysfunction, due to
the presence of metabolic/cardiovascular diseases, to the
development of major depressive disorders especially
with the presence of two or more classic risk factors.[81,82]
The MetS affects ~20%–25% of adults worldwide and
has a strong association with depression.[83,84] The
normal development of MetS is characterized by chronic
low‑grade inflammation and a pro‑oxidative environment
that negatively affects multiple vascular beds, including
in the brain. [85,86] We have recently shown that the
cerebrovascular dysfunction (impaired endothelial
function and microvascular rarefaction) with UCMS
was enhanced in the presence of MetS.[42,70] Interestingly,
these cerebrovascular adaptions to UCMS in lean
healthy rats reflect what we see in a MetS rats (without
UCMS), i.e., 8 weeks of UCMS transformed a healthy
cerebrovasculature to one with similar dysfunction
seen in the MetS. However, when chronic exposure
to stress was performed in rats that were developing
the MetS phenotype resulted in greater pathological
cerebrovascular adaptations. Unlike lean rats exposed to
UCMS, the MetS rats also developed impaired smooth
muscle dilation (endothelial‑independent dilation)
coupled with increased MCA stiffness. The profile of
47
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vasoactive metabolites was further altered with the
combined presentation of MetS and UCMS, such that the
evolving pro‑oxidant and pro‑inflammatory environment
within the cerebrovasculature nearly abolishes NO and
prostacyclin levels and further elevated thromboxane
production.[80] These results suggest that MetS results
in greater pathological cerebrovascular alterations
compared to lean rats when exposed to chronic stress.
Obesity, a major epidemic in Western societies and an
important component of the MetS, increases the severity
of cerebrovascular dysfunction. [87] Adipose tissue
conditioned media derived from lean subjects protected
neuronal cells from oxidative stress damage, however
conditioned media from adipose tissue obtained from
obese subjects lacked this protection.[88] Adipokines by
altering neuroinflammation and oxidative stress can
modulate cerebral endothelial function.[89] For example,
hypoadiponectinemia leads to endothelial dysfunction
and is a predictor of cerebrovascular events.[90,91]

Inflammatory and Oxidative Stress
Neuroinflammation and oxidative stress are implicated
in the cerebrovascular adaptations to chronic stress. The
brain is particularly susceptible to oxidative stress due
to its high levels of peroxidizable polyunsaturated fatty
acids and transition metals, the low antioxidant defense
mechanisms, and the brains high oxygen demand.[92,93]
Data from postmortem human studies have provided
strong evidence of neurovascular dysfunction with
blood‑brain barrier hyperpermeability in association
with oxidative stress and neuroinflammation.[82,94‑97] Brain
samples from individuals with major depressive disorders
have documented decreased levels of antioxidants,[93,98]
and increased levels of lipid peroxidation end products.[99]
Furthermore, an increase in serum concentrations of
malondialdehyde coupled with decreased serum levels
of nitrite, ascorbic acid, and superoxide dismutase were
noted in patients diagnosed with unipolar disorders,
compared to healthy controls.[100] Similarly, peripheral
markers of oxidation are altered in individuals with
major depressive disorders. For example, decreased
activity of antioxidant enzymes (glutathione peroxidase,
catalase, and superoxide dismutase 1), with increased
activity of pro‑oxidant enzymes (xanthine oxide),
and increased iNOS and superoxides. [92,93] Further,
support for the role of pro‑inflammatory cytokines
in stress‑induced vascular damage comes from its
actions on the peripheral vasculature. In various animal
models, pro‑inflammatory mediators IL‑6, TNF‑α,
soluble ICAM‑1, and C‑reactive protein (CRP) have
been increased following psychological stress.[101,102]
Similarly, pro‑inflammatory cytokines (IL‑6, IL‑8,
IL‑2, and CRP) have been reported to be increased
in the presence of psychological stress in several
human studies.[103‑105] There is also increased activation
48

of microglia,[106,107] upregulation of T‑helper 1 cells
and pro‑inflammatory cytokines, [108] coupled with
decreased anti‑inflammatory cytokines. [109] There is
a close relationship and a bidirectional interaction
between Inflammation and oxidative stress, whereby a
pro‑oxidative stress environment can activate microglia
and exacerbate the pro‑inflammatory reactions through
the NF‑κB pathway.[110] In turn, activated microglia and
pro‑inflammatory cytokines can perpetuate oxidative
stress.[99]
A major mechanism for the impact of oxidative stress on
vascular function is the decrease of NO bioavailability
and/or signaling. The oxidative stress induced by
stressful conditions can shift the functional balance of
NO from the beneficial endothelial NO synthase (eNOS)
generation of NO to the harmful superoxide generation
from NO. NO synthase is expressed in endothelial cells
and astrocytes as eNOS (regulates vascular smooth
muscle tone), and in the neurons as nNOS (regulates
neurotransmission). However, iNOS which occurs in the
glial and inflammatory cells is induced by pathological
inflammatory states.[94] The eNOS production of NO
increases cellular cyclic guanosine monophosphate
levels, which can increase cerebral blood flow
through endothelial‑dependent dilation.[94] However,
when combined with superoxides, the production
of NO from iNOS and nNOS can impair vascular
endothelial function and disrupt blood‑brain barrier
integrity.[94] In addition, reactive oxygen species activate
the PI3K/ras/Akt/MAPK pathway leading to redox gene
expression, which results in inhibition of eNOS mRNA
expression and eNOS activity. Increased oxidative stress
has important consequences with respect to smooth
muscle cell signaling by the soluble guanylate cyclase
and the cyclic guanosine monophosphate‑dependent
kinase I, whose activity and expression has been shown
to be regulated in a redox‑sensitive manner.[111,112] It
is well reported that pro‑inflammatory cytokines can
impact endothelial function through its actions on
decreasing eNOS activity, expression, and protein
content.[113] Interestingly, CRP at concentrations known
to predict cardiovascular disease downregulates eNOS
and destabilizes eNOS mRNA, with resultant decreases
in both basal and stimulated NO release.[114] However,
pro‑inflammatory cytokines can also alter calcium
channel expression and activity, and upregulation of
Rho‑kinase expression and function.[115,116]
In addition to an upregulation of the oxidative stress
pathway with stress, there is a decrease in the antioxidant
pathway. Seven days of exposure to stress, induced by
the social defeat model, significantly reduced protein
levels of antioxidant enzymes (glutathione reductase,
magnesium, and copper/zinc superoxide dismutase)
in the rat hippocampus but not in the amygdala or
Brain Circulation ‑ Volume 4, Issue 2, April‑June 2018
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prefrontal cortex. Concurrently, protein levels of
glyoxalase‑1 (the main enzymatic detoxification of
methylglyoxal) were also reduced in the hippocampus
and amygdala after social defeat‑induced stress.[117]
It was also noted that key second messengers, such
as calcium/calmodulin‑dependent protein kinase
type (CAMK) IV and extracellular signal‑regulated
kinase (ERK)‑1/2 were decreased and increased
respectively in the hippocampus after social stress.[117]
Calcium (Ca2+) is a universal second messenger that
regulates many diverse cellular processes including cell
proliferation, development, motility, secretion, learning,
and memory, and there is converging signaling between
CaMKII and CaMKIV. This congregated signaling
has significant physiological actions, ranging from
regulating contractile state and cellular proliferation
to Ca 2+ homeostasis and cellular permeability. [118]
Furthermore, ERK1/2 plays an important role in vascular
smooth muscle constriction,[119] and thus, an upregulation
of ERK1/2 in accordance with stress could lead to
an increase in vascular tone. Thus, it may not be
surprising to note that the changes in the oxidative
and anti‑oxidative markers were associated with
impaired cognition function with stress.[117] Overall,
these data would suggest that social defeat stress alters
ERK1/2, IL‑6, GLO1, GSR1, and CAMKIV levels in
specific brain areas, leading to oxidative stress‑induced
anxiety‑depression‑like behaviors and as well as memory
impairment in rats.
In addition to vessel reactivity, our previous efforts
into the physiological mechanisms contributing
to microvascular rarefaction in the brain [47] have
implicated the balance between oxidant stress and
endothelial function (e.g., NO bioavailability and altered
arachidonic acid metabolism) as a key contributor to the
progression and severity of microvascular rarefaction.
For example, interventions aimed at improving vascular
NO bioavailability and reducing oxidant stress (e.g.,
tempol, captopril, metformin, and rosiglitazone) were
the most effective at blunting the severity of the cortical
microvascular rarefaction.[47] With the degree of loss
in NO bioavailability reflecting the severity of the
rarefaction that followed.[47] As such the reduction in NO
bioavailability, with a corresponding higher oxidative
environment with stress in the brain, might have directly
contributed to the loss of cerebral microvessel density.

Clinical Implications
The pathophysiological adaptations that manifest
in the presence of chronic stress, especially with the
co‑occurrence of metabolic and cardiovascular diseases
could have important implications on cardiovascular
disease, cognitive impairment, Alzheimer’s disease, and
an increased risk of a cerebral infarction (stroke)[120‑124] for
Brain Circulation ‑ Volume 4, Issue 2, April‑June 2018

which impaired cerebrovascular endothelial function
is likely a contributory factor.[125] Vessel diameter and
functional hyperemic responses play a key role in
maintaining adequate blood flow to each region of
the brain, and must be able to respond accordingly
to accommodate increases in flow during periods of
higher neural activity. Impairments in any/all of these
processes would likely have significant effects on
neuronal metabolism and activity. Further, the reduction
in cerebral microvessel density (cortex and striatum)
with UCMS could have important clinical consequences.
Microvascular rarefaction affects spatial hemodynamics
and induces a non‑uniform blood flow distribution, and
has been implicated in reducing the capillary transport
of small solutes. [126] Such pathological adaptations
could also damage cerebral autoregulation and cerebral
blood flow reserve, favoring the occurrence of cognitive
impairment, and ischemic stroke.[127,128]
Lifestyle modifications such as changes in dietary
fat [129] and moderate exercise [42,130] has shown to
improve stress‑associated symptoms and lower risk to
cerebrovascular dysfunction. The impaired cognitive
function of high‑fat fed mice was improved by reduction
of dietary fat. [129] We recently showed that aerobic
exercise can protect the cerebrovascular function in
obese Zucker rats exposed to UCMS.[42] This protection
was attributed to changes in oxidative stress within the
cerebral microvasculature. Although antioxidants can
blunt most of the redox‑mediated events leading to
cerebrovascular dysfunction in animal models,[131,132] its
use clinically is still questionable.[133]

Conclusion
Chronic exposure to stress conditions leads to significant
pathophysiological alterations to the cerebrovasculature
and the creation of depressive symptoms in otherwise
healthy rats. However, these pathophysiological
responses to stress are somewhat sex‑specific and
dependent on the preexistence of metabolic and
cardiovascular diseases. Evidence would suggest
that endothelial‑dependent dysfunction is a primary
manifestation coupled with a reduction in cerebral
microvessel density of the stress response. However,
in female rats, a vascular protection exists against
chronic stress that is dependent on normal sex hormone
levels (abolished in ovariectomized mice) that better
maintains cerebral vasodilator reactivity compared to
males or females with an ovariectomy following chronic
stress. In the presence of MetS, the cerebrovascular
dysfunction and elevated depressive symptoms to
chronic stress are amplified. Further, female rats with
MetS were no longer somewhat protected from the
chronic stress response. The mechanisms behind the
cerebrovascular dysfunction are partly linked to the
49
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increased pro‑oxidative and inflammatory environment
in the brain.
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